Arcturus Therapeutics Holdings (ARCT) Stock Overview
A messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ARCT Community Fair Values
Create NarrativeSee what 47 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ST
stuart_roberts
Community ContributorUS$21.53FV • 64.4% undervalued intrinsic discount
5419.8%Revenue growth p.a.
6.2k
18
0
128
Arcturus Therapeutics Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.63 |
| 52 Week High | US$24.17 |
| 52 Week Low | US$5.85 |
| Beta | 2.44 |
| 1 Month Change | 7.47% |
| 3 Month Change | 17.10% |
| 1 Year Change | -32.74% |
| 3 Year Change | -68.16% |
| 5 Year Change | -72.86% |
| Change since IPO | -13.79% |
Recent News & Updates
ARCT: CF And OTCD Pipeline Progress Will Support Future Share Price Upside
Analysts have adjusted their price targets on Arcturus Therapeutics to a lower range, now spanning roughly $8 to $25, as they recalibrate models following Q4 updates, remove the LUNAR COVID profit share, and balance ongoing execution questions with continued confidence in the ARCT-032 and ARCT-810 programs. Analyst Commentary Recent Street research shows that while price targets on Arcturus Therapeutics have moved to a lower band, some bullish analysts still see room for upside based on the company’s clinical pipeline and execution on key programs.
ARCT: Future Execution Risks Will Drive Sensitivity To Pipeline Milestones
Analysts have modestly adjusted the average price target on Arcturus Therapeutics Holdings, reflecting updated assumptions around program execution, mixed Q4 commentary, and the removal of certain COVID-related profit share contributions, while still citing ongoing interest in cystic fibrosis and ornithine transcarbamylase deficiency programs. Analyst Commentary Recent Street research on Arcturus Therapeutics Holdings reflects a mix of cautious and constructive views, with several firms recalibrating their models after the latest Q4 update.ARCT: Fair Value View Balances Execution Concerns With Pipeline Progress
Analysts have raised the fair value estimate for Arcturus Therapeutics Holdings to $8.00 from $7.00, based on updated models that incorporate more conservative revenue expectations, higher projected profit margins and recent Street research that reduces longer term targets while still highlighting clinical progress in key programs. Analyst Commentary Recent Street research around Arcturus Therapeutics shows a mix of cautious and constructive views, with several firms revising their models after the latest quarterly update and pipeline commentary.ARCT: CF And OTCD mRNA Pipeline Progress Will Drive Future Upside
Analysts have reset their models on Arcturus Therapeutics Holdings, cutting the implied fair value estimate from about $72 to about $55 as they factor in more conservative profit margins, a slightly higher discount rate, removal of COVID-related upside, and a sharper focus on the cystic fibrosis and ornithine transcarbamylase deficiency pipelines. Analyst Commentary Recent Street research on Arcturus Therapeutics Holdings shows a wide range of fair value views, but several bullish analysts continue to see upside potential even after cutting price targets and removing COVID-related assumptions from their models.Recent updates
ARCT: CF And OTCD Pipeline Progress Will Support Future Share Price Upside
Analysts have adjusted their price targets on Arcturus Therapeutics to a lower range, now spanning roughly $8 to $25, as they recalibrate models following Q4 updates, remove the LUNAR COVID profit share, and balance ongoing execution questions with continued confidence in the ARCT-032 and ARCT-810 programs. Analyst Commentary Recent Street research shows that while price targets on Arcturus Therapeutics have moved to a lower band, some bullish analysts still see room for upside based on the company’s clinical pipeline and execution on key programs.ARCT: Future Execution Risks Will Drive Sensitivity To Pipeline Milestones
Analysts have modestly adjusted the average price target on Arcturus Therapeutics Holdings, reflecting updated assumptions around program execution, mixed Q4 commentary, and the removal of certain COVID-related profit share contributions, while still citing ongoing interest in cystic fibrosis and ornithine transcarbamylase deficiency programs. Analyst Commentary Recent Street research on Arcturus Therapeutics Holdings reflects a mix of cautious and constructive views, with several firms recalibrating their models after the latest Q4 update.ARCT: Fair Value View Balances Execution Concerns With Pipeline Progress
Analysts have raised the fair value estimate for Arcturus Therapeutics Holdings to $8.00 from $7.00, based on updated models that incorporate more conservative revenue expectations, higher projected profit margins and recent Street research that reduces longer term targets while still highlighting clinical progress in key programs. Analyst Commentary Recent Street research around Arcturus Therapeutics shows a mix of cautious and constructive views, with several firms revising their models after the latest quarterly update and pipeline commentary.ARCT: CF And OTCD mRNA Pipeline Progress Will Drive Future Upside
Analysts have reset their models on Arcturus Therapeutics Holdings, cutting the implied fair value estimate from about $72 to about $55 as they factor in more conservative profit margins, a slightly higher discount rate, removal of COVID-related upside, and a sharper focus on the cystic fibrosis and ornithine transcarbamylase deficiency pipelines. Analyst Commentary Recent Street research on Arcturus Therapeutics Holdings shows a wide range of fair value views, but several bullish analysts continue to see upside potential even after cutting price targets and removing COVID-related assumptions from their models.ARCT: Elevated Future P/E Assumptions Will Pressure Execution Risk Outlook
Analysts have raised their price target on Arcturus Therapeutics Holdings to $7.00, reflecting updated assumptions around discount rates, revenue growth, margins and future P/E, supported by a recent bullish initiation from Roth Capital and similar research commentary from other firms. Analyst Commentary While some research has turned more constructive, you are also seeing a thread of caution in recent commentary on Arcturus Therapeutics Holdings.ARCT: Bullish Coverage And Execution Risks Will Shape Fairly Valued Outlook
Analysts have raised their price target on Arcturus Therapeutics Holdings to $7.00, up from $7, citing a new bullish initiation that highlights the company’s fair value, long term revenue and margin assumptions, and expected future P/E as key supports for the revised view. Analyst Commentary While the new initiation frames US$7.00 as a reasonable reference point, bearish analysts continue to flag risks that could pressure the stock if execution does not line up with the assumptions behind that fair value, especially around long term revenue, margins, and the P/E that is being used in models.Arcturus Therapeutics: Two Catalysts, One Runway, And A Stock Priced For Failure
Feb 12ARCT: Bullish Coverage And Higher Future P/E Will Frame Execution Risks
Analysts have lifted their price target on Arcturus Therapeutics Holdings, pointing to a fair value view of US$7.00 per share. This is supported by a slightly lower discount rate, a more conservative revenue growth outlook and a higher assumed future P/E multiple, with recent bullish Street research helping to justify the updated stance.ARCT: Neutral Downgrade And Fair Value View Will Frame Execution Risks
Analysts reduced their fair value estimate for Arcturus Therapeutics Holdings from US$9.00 to US$7.00, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E following the recent downgrade to Neutral by Street research. Analyst Commentary Bearish analysts are signaling a more cautious stance on Arcturus Therapeutics Holdings, with the recent downgrade to Neutral framing the stock as more of a wait and see situation rather than a clear opportunity at current levels.ARCT: Neutral Downgrade Will Set Up Potential Upside Repricing
Analysts have reduced their price target for Arcturus Therapeutics Holdings from US$42 to US$9, citing updated assumptions for the discount rate, revenue trends, and a lower forward P/E multiple, along with recent rating changes such as the downgrade to Neutral. Analyst Commentary Bearish analysts are signaling a more cautious stance on Arcturus Therapeutics Holdings, with the move to a Neutral rating reinforcing the cut in the price target from US$42 to US$9.ARCT: Orphan mRNA Cystic Fibrosis Program Will Drive Future Upside
Analysts lowered their price target on Arcturus Therapeutics Holdings to 72 dollars from 128.81 dollars, reflecting a more cautious stance despite higher projected revenue growth and profit margins. They are reassessing valuation multiples and risk following recent rating actions.The Market Doesn't Like What It Sees From Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Revenues Yet As Shares Tumble 52%
Oct 28
Improved Revenues Required Before Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock's 32% Jump Looks Justified
Aug 29
Late-Stage Trials And Vaccine Partnerships Will Strengthen Market Potential
Analysts maintained an Overweight rating and reiterated a $47 price target for Arcturus Therapeutics Holdings, citing anticipated positive catalysts from the upcoming Phase 2 Cystic Fibrosis program readout in early Q3, while the consensus analyst price target remained unchanged at $70.89. Analyst Commentary Addition of an "upside 90-day catalyst watch" due to the upcoming Cystic Fibrosis program catalyst expected in early Q3.Is Arcturus Therapeutics Holdings (NASDAQ:ARCT) Weighed On By Its Debt Load?
Jul 31Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking After Shares Rocket 41%
May 04
KOSTAIVE Approval And Upcoming Vaccine Trials Will Open New Markets
European approval of the mRNA COVID-19 vaccine could significantly boost sales through broader market access in 31 countries.Benign Growth For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Underpins Stock's 26% Plummet
Mar 20Analysts Have Lowered Expectations For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) After Its Latest Results
Mar 09Arcturus: Downgrading As mRNA Promise Meets Market Reality
Jan 28Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data
Nov 14Improved Revenues Required Before Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock's 28% Jump Looks Justified
Oct 04Here's Why We're Not Too Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Situation
Sep 06High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine
Aug 09Arcturus: A Hidden Gem In The Biotech Sector
Jun 08Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Share Price Boosted 45% But Its Business Prospects Need A Lift Too
May 29Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis
Apr 23Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business
Apr 09Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking
Feb 06Arcturus: H1 2024 Rare Disease Drug Data On Deck
Jan 31Does Arcturus Therapeutics Holdings (NASDAQ:ARCT) Have A Healthy Balance Sheet?
Jan 11Are Investors Undervaluing Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) By 46%?
Dec 14Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Shares Lagging The Industry But So Is The Business
Sep 14Some Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Made A Major Cut To Next Year's Estimates
Aug 08Calculating The Fair Value Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)
Jul 19Shareholder Returns
| ARCT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.5% | -2.4% | 0.8% |
| 1Y | -32.7% | 27.4% | 27.8% |
Return vs Industry: ARCT underperformed the US Biotechs industry which returned 26.8% over the past year.
Return vs Market: ARCT underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| ARCT volatility | |
|---|---|
| ARCT Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ARCT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ARCT's weekly volatility has decreased from 13% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 109 | Joe Payne | arcturusrx.com |
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency.
Arcturus Therapeutics Holdings Inc. Fundamentals Summary
| ARCT fundamental statistics | |
|---|---|
| Market cap | US$245.29m |
| Earnings (TTM) | -US$65.78m |
| Revenue (TTM) | US$82.03m |
3.0x
P/S Ratio-3.7x
P/E RatioIs ARCT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARCT income statement (TTM) | |
|---|---|
| Revenue | US$82.03m |
| Cost of Revenue | US$112.21m |
| Gross Profit | -US$30.18m |
| Other Expenses | US$35.60m |
| Earnings | -US$65.78m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 07, 2026
| Earnings per share (EPS) | -2.31 |
| Gross Margin | -36.79% |
| Net Profit Margin | -80.19% |
| Debt/Equity Ratio | 0% |
How did ARCT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/03 13:54 |
| End of Day Share Price | 2026/05/01 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Arcturus Therapeutics Holdings Inc. is covered by 23 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Thomas Shrader | BTIG |